Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma develops next-generation antibody-drug conjugates for oncology through a cell-free protein engineering platform. Recurring company news covers single- and dual-payload ADC design, pipeline programs such as STRO-004, STRO-006 and STRO-227, and preclinical data across tissue factor, ITGB6 and PTK7-targeting programs.
Updates also address clinical and regulatory disclosures, research and development collaborations, operating results, financing activity, equity compensation matters, investor and scientific conference participation, and Nasdaq listing compliance. The coverage reflects Sutro’s focus on site-specific ADCs for solid tumors and other cancer indications with limited treatment options.
Sutro Biopharma (NASDAQ: STRO) announced a 1-for-10 reverse stock split of its common stock effective at 12:01 a.m. ET on December 3, 2025. The split will reduce outstanding shares from approximately 85,193,912 to approximately 8,519,392 and the post-split shares will continue to trade under the symbol STRO with a new CUSIP of 869367201.
The reverse split was previously approved by stockholders on June 6, 2025, and is intended to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Proportionate adjustments will apply to outstanding equity awards and employee plans; there will be no change to authorized shares or par value.
Sutro Biopharma (NASDAQ: STRO) hosted a virtual R&D Day on Nov 12, 2025 to detail its next‑generation ADC platform and pipeline.
Key updates: STRO‑004, a Tissue Factor ADC, has entered Phase 1 after FDA IND clearance and showed preclinical activity plus a highest non‑severely toxic dose of 50 mg/kg in non‑human primates. Sutro named PTK7 as the target for its first dual‑payload candidate STRO‑227, with an IND submission targeted for 2026/2027. STRO‑006 (ITGB6) showed superior PK versus a Phase 3 comparator and is expected to enter the clinic in 2026. Astellas collaboration and a planned iADC clinical entry are also highlighted. Initial STRO‑004 clinical data are expected mid‑2026.
Sutro Biopharma (NASDAQ: STRO) reported Q3 2025 results and program updates on Nov 6, 2025. Key developments include U.S. FDA IND clearance for STRO-004 with first patient dosing expected before year-end and preclinical safety to 50 mg/kg in non-human primates. The company highlighted advancing dual-payload ADC programs and collaboration progress with Astellas, including an IND-enabling tox study initiated in Q1 2025. As of Sept 30, 2025, cash, cash equivalents and marketable securities totaled $167.6M, with an expected cash runway into at least mid-2027, aided by cost reductions, restructuring, and expected near-term milestone payments.
Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.
The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.
Sutro Biopharma (NASDAQ: STRO) will participate at the 16th Annual World ADC Conference in San Diego, November 3-6, 2025. Sutro plans multiple presentations and panels showcasing preclinical data on site-specific, high-DAR dual-payload ADCs, immunostimulatory ADCs, cell-free antibody manufacturing, and the discovery and development of STRO-006, a Topo1-ADC targeting integrin beta-6.
Scheduled presenters include Daniel Calarese, Gang Yin, Venkatesh Srinivasan, Krishna Bajjuri, Alice Yam, and Hans-Peter Gerber, who will join panel discussions and talks across November 3-5, 2025. Presentation materials will be posted in Sutro’s Clinical/Scientific Presentation and Publication Highlights on www.sutrobio.com after the event.
Sutro Biopharma (NASDAQ: STRO), an oncology company focused on antibody drug conjugates (ADCs), announced a significant organizational restructuring to extend its cash runway into mid-2027. The restructuring involves a workforce reduction of approximately one-third of employees.
The company aims to prioritize the advancement of its three ADC programs and research collaborations. The extended runway will support key milestones, including the planned announcement of initial clinical data from STRO-004, their next-generation Tissue Factor-targeting exatecan ADC in 2026, and the initiation of clinical studies for at least one additional ADC program.
Sutro Biopharma (NASDAQ: STRO) reported its Q2 2025 financial results and business highlights, showcasing significant progress in its ADC pipeline. The company ended Q2 with $205.1 million in cash, providing runway into early 2027. Revenue surged to $63.7 million, up from $25.7 million in Q2 2024.
Key developments include preparations for STRO-004's first-in-human trial in H2 2025, advancement of STRO-006, and progress in dual-payload ADC programs. The company secured a $7.5 million milestone payment from Astellas following an IND-enabling toxicology study. Additionally, Sutro appointed Greg Chow as CFO and established a research collaboration with the FDA to enhance ADC regulatory standards.
Sutro Biopharma (NASDAQ: STRO) has announced a significant research collaboration with the FDA to advance regulatory standards for Antibody Drug Conjugates (ADCs). The partnership will utilize Sutro's proprietary XpressCF® technology to develop reference materials and enhance analytical methods for ADC drug development.
The collaboration involves Sutro working with the FDA's Office of Pharmaceutical Quality (OPQ) to jointly lead study design and selection of target antigens, payload-linkers, and drug conjugation sites. The initiative aims to improve quality assessments and regulatory standards for both approved ADCs and those in development, with results to be published upon completion.